Article Versions Notes

Lahoz S, Rodríguez A, Fernández L, Gorría T, Moreno R, Esposito F, Oliveres H, Albiol S, Saurí T, Pesantez D, et al. Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer. Cancers. 2022; 14(23):5921. https://doi.org/10.3390/cancers14235921

Lahoz, Sara, Adela Rodríguez, Laia Fernández, Teresa Gorría, Reinaldo Moreno, Francis Esposito, Helena Oliveres, Santiago Albiol, Tamara Saurí, David Pesantez, and et al. 2022. "Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer" Cancers 14, no. 23: 5921. https://doi.org/10.3390/cancers14235921

Lahoz, S., Rodríguez, A., Fernández, L., Gorría, T., Moreno, R., Esposito, F., Oliveres, H., Albiol, S., Saurí, T., Pesantez, D., Riu, G., Cuatrecasas, M., Jares, P., Pedrosa, L., Pineda, E., Postigo, A., Castells, A., Prat, A., Maurel, J., & Camps, J. (2022). Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer. Cancers, 14(23), 5921. https://doi.org/10.3390/cancers14235921